Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
Key Highlights
- ➤Acumen will report third quarter financial results on October 26, 2026
- ➤Conference call and live webcast scheduled for 8:00 a.m. ET
- ➤Phase 2 ALTITUDE-AD trial advancing sabirnetug in early symptomatic Alzheimer’s patients
- ➤Acumen is investigating subcutaneous sabirnetug using Halozyme’s ENHANZE technology
NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
Get started
Create a free account to read the full story.